View Cart (0 items)

Wyeth’s Prevnar vaccine registered in Russia

March 02, 2009
/ Print / Reprints /
| Share More
/ Text Size+
Wyeth announced that its 7-valent pneumococcal conjugate vaccine, Prevnar™ has been registered by the Russian Ministry of Health and Social Development (Roszdravnadzor) and is expected to be commercially available later this year. Prevnar, the global standard in pneumococcal disease prevention for infants and young children, helps protect against the seven pneumococcal serotypes contained in the vaccine that cause the majority of pneumococcal disease worldwide. "This important decision by Roszdravnadzor to register Prevnar is an important step forward in helping to protect the more than 1.5 million Russian children born every year from the potentially serious consequences of pneumococcal disease," says Dr. E. David McIntosh, pediatrician and Wyeth''s Medical Director for Infectious Disease and Vaccines in Europe, the Middle East and Africa. According to the World Health Organization (WHO), pneumococcal disease causes up to 1 million deaths in children each year and is the leading vaccine-preventable cause of death in children younger than five years of age worldwide. The WHO recommends priority inclusion of Prevnar (PCV7) in national childhood immunization programs worldwide due to the significant burden of pneumococcal disease and demonstrated vaccine efficacy. Prevnar is now available in more than 90 countries around the world, and 34 of those countries include Prevnar in their national childhood immunization program.
You must login or register in order to post a comment.

Related Events